Literature DB >> 26063436

Characterization of Two Human Monoclonal Antibodies Neutralizing Influenza A H7N9 Viruses.

Jianmin Wang1, Zhe Chen1, Linlin Bao2, Weijia Zhang1, Ying Xue1, XingHuo Pang3, Xi Zhang4, Chuan Qin5, Qi Jin6.   

Abstract

H7N9 was a cause of significant global health concern due to its severe infection and approximately 35% mortality in humans. By screening a Fab antibody phage library derived from patients who recovered from H7N9 infections, we characterized two human monoclonal antibodies (HuMAbs), HNIgGD5 and HNIgGH8. The epitope of these two antibodies was dependent on two residues in the receptor binding site at positions V186 and L226 of the hemagglutinin glycoprotein. Both antibodies possessed high neutralizing activity.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26063436      PMCID： PMC4524084          DOI： 10.1128/JVI.01295-15

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  14 in total

1.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

Authors:  Y Okuno; Y Isegawa; F Sasao; S Ueda
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

2.  Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.

Authors:  Thomas Zürcher; Phillip J Yates; Janet Daly; Anjali Sahasrabudhe; Matthew Walters; Laura Dash; Margaret Tisdale; Jennifer L McKimm-Breschkin
Journal:  J Antimicrob Chemother       Date:  2006-08-05       Impact factor: 5.790

3.  Influenza A (H7N9) and the importance of digital epidemiology.

Authors:  Marcel Salathé; Clark C Freifeld; Sumiko R Mekaru; Anna F Tomasulo; John S Brownstein
Journal:  N Engl J Med       Date:  2013-07-03       Impact factor: 91.245

4.  Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.

Authors:  Yunwen Hu; Shuihua Lu; Zhigang Song; Wei Wang; Pei Hao; Jianhua Li; Xiaonan Zhang; Hui-Ling Yen; Bisheng Shi; Tao Li; Wencai Guan; Lei Xu; Yi Liu; Sen Wang; Xiaoling Zhang; Di Tian; Zhaoqin Zhu; Jing He; Kai Huang; Huijie Chen; Lulu Zheng; Xuan Li; Jie Ping; Bin Kang; Xiuhong Xi; Lijun Zha; Yixue Li; Zhiyong Zhang; Malik Peiris; Zhenghong Yuan
Journal:  Lancet       Date:  2013-05-29       Impact factor: 79.321

5.  Human infection with a novel avian-origin influenza A (H7N9) virus.

Authors:  Rongbao Gao; Bin Cao; Yunwen Hu; Zijian Feng; Dayan Wang; Wanfu Hu; Jian Chen; Zhijun Jie; Haibo Qiu; Ke Xu; Xuewei Xu; Hongzhou Lu; Wenfei Zhu; Zhancheng Gao; Nijuan Xiang; Yinzhong Shen; Zebao He; Yong Gu; Zhiyong Zhang; Yi Yang; Xiang Zhao; Lei Zhou; Xiaodan Li; Shumei Zou; Ye Zhang; Xiyan Li; Lei Yang; Junfeng Guo; Jie Dong; Qun Li; Libo Dong; Yun Zhu; Tian Bai; Shiwen Wang; Pei Hao; Weizhong Yang; Yanping Zhang; Jun Han; Hongjie Yu; Dexin Li; George F Gao; Guizhen Wu; Yu Wang; Zhenghong Yuan; Yuelong Shu
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

6.  Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome.

Authors:  Yu Chen; Weifeng Liang; Shigui Yang; Nanping Wu; Hainv Gao; Jifang Sheng; Hangping Yao; Jianer Wo; Qiang Fang; Dawei Cui; Yongcheng Li; Xing Yao; Yuntao Zhang; Haibo Wu; Shufa Zheng; Hongyan Diao; Shichang Xia; Yanjun Zhang; Kwok-Hung Chan; Hoi-Wah Tsoi; Jade Lee-Lee Teng; Wenjun Song; Pui Wang; Siu-Ying Lau; Min Zheng; Jasper Fuk-Woo Chan; Kelvin Kai-Wang To; Honglin Chen; Lanjuan Li; Kwok-Yung Yuen
Journal:  Lancet       Date:  2013-04-25       Impact factor: 79.321

7.  Human monoclonal antibodies broadly neutralizing against influenza B virus.

Authors:  Mayo Yasugi; Ritsuko Kubota-Koketsu; Akifumi Yamashita; Norihito Kawashita; Anariwa Du; Tadahiro Sasaki; Mitsuhiro Nishimura; Ryo Misaki; Motoki Kuhara; Naphatsawan Boonsathorn; Kazuhito Fujiyama; Yoshinobu Okuno; Takaaki Nakaya; Kazuyoshi Ikuta
Journal:  PLoS Pathog       Date:  2013-02-07       Impact factor: 6.823

8.  The genesis and source of the H7N9 influenza viruses causing human infections in China.

Authors:  Tommy Tsan-Yuk Lam; Jia Wang; Yongyi Shen; Boping Zhou; Lian Duan; Chung-Lam Cheung; Chi Ma; Samantha J Lycett; Connie Yin-Hung Leung; Xinchun Chen; Lifeng Li; Wenshan Hong; Yujuan Chai; Linlin Zhou; Huyi Liang; Zhihua Ou; Yongmei Liu; Amber Farooqui; David J Kelvin; Leo L M Poon; David K Smith; Oliver G Pybus; Gabriel M Leung; Yuelong Shu; Robert G Webster; Richard J Webby; Joseph S M Peiris; Andrew Rambaut; Huachen Zhu; Yi Guan
Journal:  Nature       Date:  2013-08-21       Impact factor: 49.962

9.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.

Authors:  Elisabetta Traggiai; Stephan Becker; Kanta Subbarao; Larissa Kolesnikova; Yasushi Uematsu; Maria Rita Gismondo; Brian R Murphy; Rino Rappuoli; Antonio Lanzavecchia
Journal:  Nat Med       Date:  2004-07-11       Impact factor: 53.440

10.  Receptor binding by an H7N9 influenza virus from humans.

Authors:  Xiaoli Xiong; Stephen R Martin; Lesley F Haire; Stephen A Wharton; Rodney S Daniels; Michael S Bennett; John W McCauley; Patrick J Collins; Philip A Walker; John J Skehel; Steven J Gamblin
Journal:  Nature       Date:  2013-07-25       Impact factor: 49.962
View more
  8 in total

Review 1.  Avian influenza A (H7N9) virus: from low pathogenic to highly pathogenic.

Authors:  William J Liu; Haixia Xiao; Lianpan Dai; Di Liu; Jianjun Chen; Xiaopeng Qi; Yuhai Bi; Yi Shi; George F Gao; Yingxia Liu
Journal:  Front Med       Date:  2021-04-16       Impact factor: 4.592

2.  Broad neutralizing activity of a human monoclonal antibody against H7N9 strains from 2013 to 2017.

Authors:  Cong Chen; Zuliang Liu; Liguo Liu; Yan Xiao; Jianmin Wang; Qi Jin
Journal:  Emerg Microbes Infect       Date:  2018-11-14       Impact factor: 7.163

3.  Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset.

Authors:  Zhe Chen; Linlin Bao; Cong Chen; Tingting Zou; Ying Xue; Fengdi Li; Qi Lv; Songzhi Gu; Xiaopan Gao; Sheng Cui; Jianmin Wang; Chuan Qin; Qi Jin
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

4.  Nanobodies mapped to cross-reactive and divergent epitopes on A(H7N9) influenza hemagglutinin using yeast display.

Authors:  Tiziano Gaiotto; Walter Ramage; Christina Ball; Paul Risley; George W Carnell; Nigel Temperton; Othmar G Engelhardt; Simon E Hufton
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.996

5.  Immune Escape Adaptive Mutations in the H7N9 Avian Influenza Hemagglutinin Protein Increase Virus Replication Fitness and Decrease Pandemic Potential.

Authors:  Pengxiang Chang; Joshua E Sealy; Jean-Remy Sadeyen; Sushant Bhat; Deimante Lukosaityte; Yipeng Sun; Munir Iqbal
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

6.  Amino Acid Residue 217 in the Hemagglutinin Glycoprotein Is a Key Mediator of Avian Influenza H7N9 Virus Antigenicity.

Authors:  Pengxiang Chang; Joshua E Sealy; Jean-Remy Sadeyen; Munir Iqbal
Journal:  J Virol       Date:  2018-12-10       Impact factor: 5.103

7.  A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin.

Authors:  Fei Yu; He Song; Yanling Wu; So Young Chang; Lili Wang; Wei Li; Binbin Hong; Shuai Xia; Chunyu Wang; Surender Khurana; Yang Feng; Yanping Wang; Zhiwu Sun; Biao He; Dongni Hou; Jody Manischewitz; Lisa R King; Yuanlin Song; Ji-Young Min; Hana Golding; Xinhua Ji; Lu Lu; Shibo Jiang; Dimiter S Dimitrov; Tianlei Ying
Journal:  Cell Host Microbe       Date:  2017-09-28       Impact factor: 21.023

Review 8.  Development of therapeutic antibodies for the treatment of diseases.

Authors:  Ruei-Min Lu; Yu-Chyi Hwang; I-Ju Liu; Chi-Chiu Lee; Han-Zen Tsai; Hsin-Jung Li; Han-Chung Wu
Journal:  J Biomed Sci       Date:  2020-01-02       Impact factor: 8.410
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.